CIK: 0001704132 · Show all filings
Period: Q4 2018 (← Previous) (Next →)
Filing Date: Feb 13, 2019
Total Value ($000): $217,868 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | Biohaven Pharmaceutical Holding Company Ltd. | 855,900 | $31,651 | 14.5% | $26.07 | — | COM | G11196105 |
| INSM | Insmed Incorporated | 1,977,236 | $25,941 | 11.9% | $26.83 | -40.5% | COM | 457669307 |
| — | Myokardia, Inc. | 486,624 | $23,776 | 10.9% | $45.40 | — | COM | 62857M105 |
| — | CymaBay Therapeutics, Inc. | 2,631,258 | $20,708 | 9.5% | $8.89 | — | COM | 23257D103 |
| — | Immunomedics, Inc. | 1,205,363 | $17,201 | 7.9% | $17.13 | — | COM | 452907108 |
| ASND | Ascendis Pharma A/S | 245,424 | $15,376 | 7.1% | $40.06 | — | SPONSORED ADR | 04351P101 |
| REPL | Replimune Group, Inc. | 1,229,656 | $12,297 | 5.6% | $17.53 | -22.9% | COM | 76029N106 |
| RYTM | Rhythm Pharmaceuticals, Inc. | 400,000 | $10,752 | 4.9% | $27.09 | +2.0% | COM | 76243J105 |
| — | OptiNose, Inc. | 1,708,545 | $10,593 | 4.9% | $17.42 | — | COM | 68404V100 |
| — | Orchard Therapeutics PLC | 668,361 | $10,513 | 4.8% | $15.73 | — | ADS | 68570P101 |
| — | Aerie Pharmaceuticals, Inc. | 261,823 | $9,452 | 4.3% | $36.10 | — | COM | 00771V108 |
| ABUS | Arbutus Biopharma Corporation | 1,582,275 | $6,060 | 2.8% | $5.62 | -12.3% | COM | 03879J100 |
| — | Eidos Therapeutics, Inc. | 431,781 | $5,941 | 2.7% | $14.82 | — | COM | 28249H104 |
| ACRS | Aclaris Therapeutics, Inc. | 748,132 | $5,529 | 2.5% | $18.71 | -44.9% | COM | 00461U105 |
| — | Portola Pharmaceuticals, Inc. | 250,000 | $4,880 | 2.2% | $19.52 | — | COM | 737010108 |
| SIBN | SI-BONE, Inc. | 205,621 | $4,295 | 2.0% | $18.92 | 0.0% | COM | 825704109 |
| — | Kiniksa Pharmaceuticals, Ltd. | 63,922 | $1,796 | 0.8% | $17.35 | — | Class A Common | G5269C101 |
| CYTK | Cytokinetics Incorporated | 175,148 | $1,107 | 0.5% | $7.34 | 0.0% | COM NEW | 23282W605 |